SOURCE: Gene Express, Inc.

November 13, 2006 08:30 ET

Gene Express Appoints Colette Saccomanno, Ph.D. Director of Business Development

Adds More Than a Decade of Sales and Marketing Experience in Life Sciences Technologies, Products and Services

TOLEDO, OH -- (MARKET WIRE) -- November 13, 2006 -- Gene Express, Inc. today announced the appointment of Colette Saccomanno, Ph.D. as Director of Business Development.

Gerald Vardzel, CEO of Gene Express, commented, "We are pleased to have the benefit of Dr. Saccomanno's expertise in positioning innovative technologies among key participants in the life sciences marketplace. She understands our client and partner base well and will be instrumental in driving our sales and partnering strategies forward."

Dr. Saccomanno has over a decade of experience in sales and marketing of life sciences technologies, products and services. Most recently, Dr. Saccomanno was Program Manager at ArisGlobal, where her clients included pharmaceutical, medical device, biotechnology companies, clinical research organizations and research institutions. Prior to this, she served as a Senior Account Executive at Galt Associates (recently acquired by Cerner), where she closed two consulting deals worth over $100,000 in her first month with the company.

Dr. Saccomanno held the position of Account Executive at several companies including Covance Laboratories' Early Development division, Vysis (now Abbott Molecular) and the Clinical Diagnostics Group of Bio-Rad Laboratories. She gained international experience as a consultant to Nordic Biosciences A/S, where she assessed the need for a North American sales presence and served as their liaison to the US Food and Drug Administration. She has also served as a grant reviewer for the U.S. Department of Defense Congressionally Directed Medical Research Programs for Neurofibromatosis.

Dr. Saccomanno received her Ph.D. in Biological Sciences with an emphasis in RNA processing and gene expression from Fordham University in the Bronx, New York in 1994. She will soon complete requirements for a Masters Degree in Library and Information Sciences at Pratt Institute in New York.

Dr. Saccomanno stated, "I am very excited to be a part of the Gene Express team. My academic interest in gene expression and my experience in selling into this market allowed me to recognize that the StaRT-PCR™ technology will revolutionize the way we approach drug development. I am thrilled to be a member of the team that will help make personalized medicine a reality much faster than most thought possible."

About Gene Express, Inc.

Gene Express, Inc. accelerates and enables drug development by providing standardized genomic data. The Company's proprietary and patented StaRT-PCR™ (Standardized Reverse Transcriptase Polymerase Chain Reaction) platform technology for measuring gene expression levels in cells, tissue and blood is being used by numerous pharmaceutical concerns, as well as leading academic centers. The Company's $3 billion focus market for licensing and contract services includes the drug development, academic and molecular diagnostics segments. Additional information is available on the Company's website at www.geneexpressinc.com.

Any forecasts, plans, projections and other information contained in this press release describing events or results that may occur in the future are "forward-looking statements" as defined in the United States Private Securities litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and important factors that are beyond the control of the Company that could cause actual results and events to differ materially from the results presently anticipated or projected. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to this cautionary statement. All forward-looking statements contained herein speak only as of the date of this release and are based on current expectations. The Company disclaims any obligation to update or revise any forward-looking statements.

Contact Information

  • Contact:
    Rachel Levine
    The Global Consulting Group
    Tel: 646-284-9439
    E: Email Contact